Stock listing
NASDAQ:ACRS Aclaris Therapeutics, Inc. Stock
Home listing (NASDAQ) of Aclaris Therapeutics, Inc.
Follow Aclaris Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ACRS
$3.90 USD +0.29 (+8.0%)
Close on Nov 6, 2026
- Day range
- $3.61 – $3.98 USDNov 6, 2026
- Volume
- 3.53M sharesNov 6, 2026
- Market cap
- $574.1M USDAt the close on Nov 6, 2026 · price × 147.2M shares outstanding
- 52-week range
- $2.10 – $6.60 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- $13.41M USDMedian day 2.28M shares · last 3 months, Aug 6, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACRS · Home | $3.90 USD | +0.29 (+8.0%) | 3,526,370 | $3.62 | $3.975 | $3.61 | $3.61 | Close on Nov 6, 2026 |
| LSE:0H8T | $3.865 USD | +0.265 (+7.4%) | 1,451 | $3.625 | $3.921 | $3.56 | $3.60 | Close on Nov 6, 2026 |
| Frankfurt:8AT | €3.152 EUR | -0.116 (-3.5%) | — | €3.152 | €3.152 | €3.152 | €3.268 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · NASDAQ:ACRS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.90 | +0.29 | +8.0% | $3.62 | $3.975 | $3.61 | 3,526,370 | |
| $3.61 | -0.07 | -1.9% | $3.71 | $3.72 | $3.45 | 2,330,021 | |
| $3.68 | -0.06 | -1.6% | $3.81 | $3.88 | $3.63 | 2,045,268 | |
| $3.74 | -0.06 | -1.6% | $3.83 | $3.94 | $3.665 | 1,865,670 | |
| $3.80 | -0.17 | -4.3% | $4.085 | $4.085 | $3.765 | 1,644,578 | |
| $3.97 | -0.02 | -0.5% | $4.00 | $4.07 | $3.87 | 1,880,494 | |
| $3.99 | +0.03 | +0.8% | $4.01 | $4.079 | $3.96 | 1,458,255 | |
| $3.96 | +0.17 | +4.5% | $3.70 | $3.975 | $3.66 | 3,878,316 | |
| $3.79 | 0.00 | 0.0% | $3.98 | $4.00 | $3.44 | 7,986,058 | |
| $3.79 | +0.04 | +1.1% | $3.78 | $3.85 | $3.715 | 1,572,729 | |
| $3.75 | -0.08 | -2.1% | $3.81 | $3.845 | $3.681 | 2,290,472 | |
| $3.83 | +0.02 | +0.5% | $3.77 | $3.98 | $3.735 | 2,799,030 | |
| $3.81 | +0.04 | +1.1% | $3.74 | $3.97 | $3.69 | 2,662,726 | |
| $3.77 | +0.29 | +8.3% | $3.41 | $3.81 | $3.37 | 3,499,198 | |
| $3.48 | +0.20 | +6.1% | $3.28 | $3.50 | $3.255 | 1,747,414 | |
| $3.28 | -0.21 | -6.0% | $3.51 | $3.53 | $3.245 | 2,457,047 | |
| $3.49 | +0.11 | +3.3% | $3.42 | $3.505 | $3.34 | 2,587,484 | |
| $3.38 | -0.09 | -2.6% | $3.38 | $3.47 | $3.34 | 2,589,455 | |
| $3.47 | -0.13 | -3.6% | $3.65 | $3.652 | $3.41 | 3,439,350 | |
| $3.60 | -0.23 | -6.0% | $3.80 | $3.835 | $3.585 | 3,428,985 | |
| $3.83 | +0.04 | +1.1% | $3.76 | $3.94 | $3.64 | 5,060,059 | |
| $3.79 | +0.39 | +11.5% | $3.37 | $3.815 | $3.182 | 8,735,450 | |
| $3.40 | -0.30 | -8.1% | $3.595 | $3.62 | $3.315 | 9,003,171 | |
| $3.70 | -0.57 | -13.3% | $4.22 | $4.24 | $3.65 | 3,531,028 | |
| $4.27 | -0.12 | -2.7% | $4.34 | $4.41 | $4.065 | 7,015,490 | |
| $4.39 | -0.02 | -0.5% | $4.44 | $4.52 | $4.205 | 6,208,852 | |
| $4.41 | -0.85 | -16.2% | $5.18 | $5.18 | $4.35 | 5,177,064 | |
| $5.26 | -0.02 | -0.4% | $5.30 | $5.395 | $5.21 | 2,263,473 | |
| $5.28 | -0.15 | -2.8% | $5.42 | $5.45 | $5.155 | 2,051,711 | |
| $5.43 | +0.28 | +5.4% | $5.07 | $5.465 | $5.02 | 2,429,167 | |
| $5.15 | -0.23 | -4.3% | $5.39 | $5.538 | $5.095 | 1,474,099 | |
| $5.38 | +0.12 | +2.3% | $5.24 | $5.44 | $5.145 | 2,488,961 | |
| $5.26 | -0.46 | -8.0% | $5.70 | $5.74 | $5.035 | 1,962,832 | |
| $5.72 | +0.15 | +2.7% | $5.63 | $5.765 | $5.50 | 2,879,401 | |
| $5.57 | +0.07 | +1.3% | $5.55 | $5.62 | $5.40 | 1,521,430 | |
| $5.50 | +0.10 | +1.9% | $5.41 | $5.535 | $5.36 | 4,688,000 | |
| $5.40 | +0.08 | +1.5% | $5.37 | $5.625 | $5.34 | 3,822,975 | |
| $5.32 | -0.205 | -3.7% | $5.54 | $5.56 | $4.975 | 5,771,579 | |
| $5.525 | -0.115 | -2.0% | $5.60 | $5.62 | $5.405 | 1,331,161 | |
| $5.64 | +0.32 | +6.0% | $5.29 | $5.715 | $5.29 | 5,838,426 | |
| $5.32 | -0.185 | -3.4% | $5.50 | $5.595 | $5.17 | 3,278,158 | |
| $5.505 | -0.055 | -1.0% | $5.55 | $5.555 | $5.385 | 2,210,625 | |
| $5.56 | -0.50 | -8.3% | $6.075 | $6.075 | $5.41 | 3,679,404 | |
| $6.06 | -0.11 | -1.8% | $6.08 | $6.145 | $5.915 | 3,060,924 | |
| $6.17 | +0.22 | +3.7% | $5.965 | $6.195 | $5.87 | 1,746,645 | |
| $5.95 | -0.23 | -3.7% | $6.24 | $6.27 | $5.895 | 1,392,061 | |
| $6.18 | +0.16 | +2.7% | $6.09 | $6.24 | $5.875 | 1,550,402 | |
| $6.02 | -0.03 | -0.5% | $6.09 | $6.24 | $5.95 | 1,487,103 | |
| $6.05 | +0.04 | +0.7% | $5.97 | $6.06 | $5.845 | 1,633,151 | |
| $6.01 | -0.15 | -2.4% | $6.10 | $6.18 | $5.95 | 1,220,840 | |
| $6.16 | -0.03 | -0.5% | $6.15 | $6.305 | $6.12 | 1,408,995 | |
| $6.19 | -0.345 | -5.3% | $6.53 | $6.53 | $6.07 | 1,736,052 | |
| $6.535 | +0.225 | +3.6% | $6.36 | $6.60 | $6.15 | 3,353,244 | |
| $6.31 | -0.10 | -1.6% | $6.35 | $6.40 | $6.02 | 1,272,816 | |
| $6.41 | +0.08 | +1.3% | $6.36 | $6.50 | $6.29 | 2,208,483 | |
| $6.33 | -0.11 | -1.7% | $6.35 | $6.46 | $6.17 | 1,514,519 | |
| $6.44 | +0.135 | +2.1% | $6.40 | $6.449 | $6.20 | 2,065,238 | |
| $6.305 | +0.385 | +6.5% | $5.88 | $6.315 | $5.854 | 2,012,740 | |
| $5.92 | +0.14 | +2.4% | $5.72 | $5.955 | $5.685 | 1,086,354 | |
| $5.78 | -0.08 | -1.4% | $5.82 | $5.855 | $5.64 | 666,268 | |
| $5.86 | +0.02 | +0.3% | $5.90 | $6.055 | $5.812 | 1,065,838 | |
| $5.84 | -0.08 | -1.4% | $5.94 | $5.97 | $5.84 | 937,108 | |
| $5.92 | +0.02 | +0.3% | $5.90 | $5.935 | $5.80 | 1,210,253 | |
| $5.90 | -0.01 | -0.2% | $5.92 | $5.99 | $5.67 | 1,593,821 | |
| $5.91 | -0.18 | -3.0% | $6.08 | $6.23 | $5.65 | 2,388,049 | |
| $6.09 | -0.27 | -4.2% | $6.34 | $6.44 | $5.90 | 2,821,806 |
- Ticker
- NASDAQ:ACRS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Latest deck · Oct 27, 2026
Technical Presentation (October 2026)
Technical · 34 slides
Calls
Replays
Aclaris Therapeutics (NASDAQ:ACRS) Q1 2024 Earnings Call
Tue, May 07, 2024 · 5:00 PM ET
Watch TranscriptAclaris Therapeutics (NASDAQ:ACRS) Q1 2023 Earnings Call
Mon, May 08, 2023 · 8:00 AM ET
Watch Transcript
Latest news
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Nov 5, 2026
Closed $3.61 (-1.9%) on Nov 5, 2026
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
Oct 27, 2026
Closed $3.79 (0.0%) on Oct 27, 2026
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
Oct 27, 2026
Closed $3.79 (0.0%) on Oct 27, 2026
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Sep 3, 2026
Closed $5.95 (-3.7%) on Sep 3, 2026
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aug 6, 2026
Closed $6.09 (-4.2%) on Aug 6, 2026
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Closed $4.57 (-0.2%) on May 28, 2026
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
May 8, 2026
Closed $4.93 (+1.4%) on May 8, 2026
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
May 7, 2026
Closed $4.86 (+1.7%) on May 7, 2026
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indicati...
Apr 28, 2026
Closed $4.22 (-4.3%) on Apr 28, 2026
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Apr 27, 2026
Closed $4.22 (-4.3%) on Apr 28, 2026
Financings
Public offering of common stock and pre-funded warrants
Oct 27, 2026
Announced: about US$50M · US$3.5 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Cantor (co-lead), LifeSci Capital (co-lead)
Buyers: TCGX; RA Capital Management; Invus
Private placement of shares of common stock
Nov 18, 2024
Announced: about US$80M · US$2.25 a share · Leerink Partners +1
Dealers: Leerink Partners, Cantor
Buyers: Vivo Capital (led the private placement); Forge Life Science Partners; Rock Springs Capital; RA Capital Management; Adage Capital Partners LP; Decheng Capital; Logos Capital; Samsara BioCapital
Use of proceeds: Research and development of its pipeline and general corporate purposes
Decks
Technical Presentation (October 2026)
Technical · 34 slides · Oct 27, 2026
Investor Presentation (August 2026)
Investor deck · 33 slides · August 2026
Corporate Update (April 2026)
Corporate update · 30 slides · Apr 28, 2026
Investor Presentation (January 2026)
Investor deck · 65 slides · Jan 12, 2026
Aclaris Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 133 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 2 calls with a replay · 2 with a transcript · latest May 7, 2024
- Decks
- 41 decks · latest Oct 27, 2026
Where Aclaris Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACRS · Home listing · This page | NASDAQ | United States | USD |
| gettex:8AT | gettex | Germany | EUR |
| Tradegate:8AT | Tradegate | Germany | EUR |
| LS Exchange:A1412H | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1412H | Lang & Schwarz | Germany | EUR |
| LSE:0H8T | LSE | United Kingdom | USD |
| BOATS:ACRS | BOATS | United States | USD |
| Stuttgart:8AT | Stuttgart | Germany | EUR |
| Dusseldorf:8AT | Dusseldorf | Germany | EUR |
| Frankfurt:8AT | Frankfurt | Germany | EUR |
| Munich:8AT | Munich | Germany | EUR |
Log in to ask 6ix AI your own questions about Aclaris Therapeutics, Inc.